A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

Trial Profile

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Anal cancer; Biliary cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Gynaecological cancer; Lung cancer; Mesothelioma; Neuroendocrine tumours; Salivary gland cancer; Small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-158
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Sep 2017 Results of this trial (n=77, data cut-off date: Jan 27, 2017) and another trial (refer CTP: 700257556, n=61, data cut-off date: Feb 10, 2017) presented at the 42nd European Society for Medical Oncology Congress
    • 13 Jun 2017 Planned End Date changed from 1 May 2019 to 28 Aug 2023.
    • 13 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 28 Aug 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top